Next Article in Journal
Supply-Side and Demand-Side Policies for Biosimilars: An Overview in 10 European Member States
Previous Article in Journal
Do Payers Value Rarity? An Analysis of the Relationship between Disease Rarity and Orphan Drug Prices in Europe
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 5
Issue 1
10.1080/20016689.2017.1299833
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Filling the Gap in CNS Drug Development: Evaluation of the Role of Drug Repurposing

by
A. Caban
1,*,
K. Pisarczyk
1,
K. Kopacz
1,
A. Kapuśniak
1,
M. Toumi
2,
C. Rémuzat
3 and
A. Kornfeld
3
1
Creativ-Ceutical, Pricing & Market Access Department, Krakow, Poland
2
Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille Cedex, France
3
Creativ-Ceutical, Pricing & Market Access Department, Paris, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2017, 5(1), 1299833; https://doi.org/10.1080/20016689.2017.1299833 (registering DOI)
Submission received: 24 January 2017 / Revised: 1 January 2017 / Accepted: 15 February 2017 / Published: 10 April 2017
Versions Notes

Abstract

Background and objective: Drug repurposing has been considered a cost-effective and reduced-risk strategy for developing new drugs. Little is known and documented regarding the efficiency of repurposing strategies in drug development. The objective of this article is to assess the extent and meaning of this process in the CNS area. Methods: In order to identify repurposed drugs that target the CNS, an extensive search was performed. For each identified case, its initial and target indication, development status and the type of repurposing strategy (repositioning, reformulation or both) was recorded. Results: One hundred and eighteen source products were identified. They were repurposed (mainly repositioned) 203 times with 81 products repurposed once and 38 products repurposed twice or more. The highest number of source drugs originated from the CNS area. Alzheimer’s disease was targeted most often. Half of the new indications were approved. Regarding repurposing within the CNS area, epilepsy, schizophrenia and depression were the richest sources of repurposed drugs. Conclusions: Repurposing drugs into CNS is an efficient and very active drug development method, exemplified by the considerable number of new indications that have been found via this strategy, with approximately half of the target indications currently under development.
Keywords: drug repurposing; drug repositioning; drug reprofiling; drug retasking; central nervous system; psychiatry; neurology drug repurposing; drug repositioning; drug reprofiling; drug retasking; central nervous system; psychiatry; neurology

Share and Cite

MDPI and ACS Style

Caban, A.; Pisarczyk, K.; Kopacz, K.; Kapuśniak, A.; Toumi, M.; Rémuzat, C.; Kornfeld, A. Filling the Gap in CNS Drug Development: Evaluation of the Role of Drug Repurposing. J. Mark. Access Health Policy 2017, 5, 1299833. https://doi.org/10.1080/20016689.2017.1299833

AMA Style

Caban A, Pisarczyk K, Kopacz K, Kapuśniak A, Toumi M, Rémuzat C, Kornfeld A. Filling the Gap in CNS Drug Development: Evaluation of the Role of Drug Repurposing. Journal of Market Access & Health Policy. 2017; 5(1):1299833. https://doi.org/10.1080/20016689.2017.1299833

Chicago/Turabian Style

Caban, A., K. Pisarczyk, K. Kopacz, A. Kapuśniak, M. Toumi, C. Rémuzat, and A. Kornfeld. 2017. "Filling the Gap in CNS Drug Development: Evaluation of the Role of Drug Repurposing" Journal of Market Access & Health Policy 5, no. 1: 1299833. https://doi.org/10.1080/20016689.2017.1299833

APA Style

Caban, A., Pisarczyk, K., Kopacz, K., Kapuśniak, A., Toumi, M., Rémuzat, C., & Kornfeld, A. (2017). Filling the Gap in CNS Drug Development: Evaluation of the Role of Drug Repurposing. Journal of Market Access & Health Policy, 5(1), 1299833. https://doi.org/10.1080/20016689.2017.1299833

Article Metrics

Back to TopTop